Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib

Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners

(2016) Jeff Elleraas et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging

(2016) Steven H. Liang et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

ALK inhibitors: plateauing systemic and intracranial activity?

(2016) Daniel B Costa   LANCET ONCOLOGY

Mechanistic studies and radiofluorination of structurally diverse pharmaceuticals with spirocyclic iodonium(iii) ylides

(2016) Benjamin H. Rotstein et al.   Chemical Science

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

(2016) J. F. Gainor et al.   Cancer Discovery

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

(2015) Helen Y. Zou et al.   CANCER CELL

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non–Small Cell Lung Cancer

(2015) Wade T. Iams et al.   CANCER JOURNAL

Novel ALK inhibitors in clinical use and development

(2015) Chaitanya Iragavarapu et al.   Journal of Hematology & Oncology

Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

(2015) Qingbei Zeng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Iodonium Ylide-Mediated Radiofluorination of 18F-FPEB and Validation for Human Use

(2015) N. A. Stephenson et al.   JOURNAL OF NUCLEAR MEDICINE

Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging

(2015) Vadim Bernard-Gauthier et al.   MOLECULES

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

(2015) Helen Y. Zou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Macrocycles: lessons from the distant past, recent developments, and future directions

(2015) Andrei K. Yudin   Chemical Science

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data

(2015) Gouji Toyokawa et al.   Oncology Research and Treatment

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

(2015) Meghan Shea et al.   Therapeutic Advances in Respiratory Disease

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance

(2015) Zilan Song et al.   Acta Pharmaceutica Sinica B

U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive

(2014) S. M. Malik et al.   CLINICAL CANCER RESEARCH

Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

(2014) Ted W. Johnson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Optimization of nucleophilic 18F radiofluorinations using a microfluidic reaction approach

(2014) Giancarlo Pascali et al.   Nature Protocols

Spirocyclic hypervalent iodine(III)-mediated radiofluorination of non-activated and hindered aromatics

(2014) Benjamin H. Rotstein et al.   Nature Communications

The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer

(2013) Manolo D’Arcangelo et al.   CURRENT OPINION IN ONCOLOGY

Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque

(2013) Jason P. Holland et al.   JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS

PET of Signal Transduction Pathways in Cancer

(2012) J. P. Holland et al.   JOURNAL OF NUCLEAR MEDICINE

Radiolabeling of [18F]altanserin — a microfluidic approach

(2012) Johanna Ungersboeck et al.   NUCLEAR MEDICINE AND BIOLOGY

Optimization of the radiosynthesis of the Alzheimer tracer 2-(4-N-[11C]methylaminophenyl)-6-hydroxybenzothiazole ([11C]PIB)

(2011) C. Philippe et al.   APPLIED RADIATION AND ISOTOPES

Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies

(2011) Paolo Zanotti-Fregonara et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

(2011) Daniel B. Costa et al.   JOURNAL OF CLINICAL ONCOLOGY

Fully automated and reproducible radiosynthesis of high specific activity [11C]raclopride and [11C]Pittsburgh compound-B using the combination of two commercial synthesizers

(2011) Vanessa Gómez-Vallejo et al.   NUCLEAR MEDICINE COMMUNICATIONS

The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene

(2010) Fergal C. Kelleher et al.   EUROPEAN JOURNAL OF CANCER

Radiolabeled Small Molecule Protein Kinase Inhibitors for Imaging with PET or SPECT

(2010) Justin W. Hicks et al.   MOLECULES